肺癌患者调节性T细胞的变化及CpG ODN的干预作用

目的:观察肺癌患者外周血调节性T细胞的变化,并探讨CpG ODN的干预作用。方法:分离肺癌患者和健康志愿者(各30例)的外周血单个核细胞(PBMC),用流式细胞仪检测CD4+CD25+调节性T细胞比例,Real-time PCR检测Foxp3基因的表达,ELISA法检测TGF-β和IFN-γ水平。将30例肺癌患者的PBMC随机分为实验组和安慰剂组,分别给予CpG ODN2006或安慰剂CpG ODN1612干预,比较干预前后上述指标的变化。结果:肺癌患者PBMC中的CD4+CD25+调节性T细胞比例、Foxp3基因的相对表达量、TGF-β水平均高于健康对照组,差异具有显著性,但不同病理分型和分期的肺癌患者亚组间比较无显著性差异。两组的IFN-γ水平比较无差异性。CpG ODN干预后CpG ODN2006治疗组的CD4+CD25+调节性T细胞比例、Foxp3基因的相对表达量及TGF-β水平出现了下降,差异有显著性,IFN-γ水平变化无显著性差异。而CpG ODN1612安慰剂组的上述指标在干预前后则无显著性改变。结论:肺癌患者外周血中的CD4+CD25+Foxp3+调节性T细胞比例、TGF-β水平明显升高。CpG ODN2006干预可下调CD4+CD25+Foxp3+调节性T细胞比例及TGF-β水平。

The change of regulatory T cells of PBMC and the effects of CpG ODN in patients with lung cancer

Objective:To study the change of regulatory T cells in PBMC and the effects of CpG ODN in patients with lung cancer.Methods: Lymphocytes isolated from blood of 30 patients with lung canaer and 30 healthy volunteers were analyzed for the proportion of CD4 ~+CD25~+ T cells by flow cytometry.The mRNA expression of Foxp3 was detected by real-time PCR and the levels of TGF-β and IFN-γ were tested by ELLSA.The PBMC of 30 patients with lung cancer were randomly divided into treated group(CpG ODN 2006)and placebo group(CpG ODN 1612).The proportion of CD4 ~+ CD25~+ T cells,the mRNA expression of Foxp3 and the levels of TGF-β and IFN-γ were compared before and after treatment.Results:Tbe proportion of CD4~+ CD25~+ T cells,the mRNA expression of Foxp3 and the levels of TGF-β in patients with lung cancer were higher than those in healthy volunteers,but there was no significant difference in such parameters among subgroups of pathologic classification and clinical stage patients.The proportion of CD4 ~+ CD25~+ T cells, the mRNA expression of Foxp3 and the levels of TGF-β were dropped in CpG ODN 2006 group after treatment.There was no significant difference in these parameters before and after treatment in CpG ODN 1612 group.Conclusion: The proportion of CD4~+ CD25 ~+ T cells, the mRNA expression of Foxp3 and the levels of TGF-β of PBMC in lung cancer patients are higher than those in healthy volunteers.Treating by CpG ODN 2006 could down-regulate the proportion of CD4~+ CD25~+ Foxp3~+ regulatory T cells and the levels of TGF-β of PBMC from the patients with lung cancer.